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Abstract
Each year, at least 280,000 children are born with sickle cell disease (SCD) in resource-limited settings. For cost,
logistic and political reasons, the availability of SCD testing is limited in such settings and consequently 50–90 % of
affected children die undiagnosed before their fifth birthday. The recent development of a point of care method
for the diagnosis of SCD – the Sickle SCAN™ device – could afford such children the prompt access to appropriate
services that has transformed the outlook for affected children in resource-rich areas. In research published in BMC
Medicine, Kanter and colleagues describe a small but carefully conducted study involving 208 children and adults, in
which they found that by using Sickle SCAN™ it was possible to diagnose the common forms of SCD with 99 %
sensitivity and 99 % specificity, in under 5 minutes. If repeatable both in newborn babies and under real-life
conditions, and if marketed at an affordable price, Sickle SCAN™ could revolutionize the survival prospects for
children born with SCD in resource-limited areas.
Please see related article: http://dx.doi.org/10.1186/s12916-015-0473-6.
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Background
Sickle cell disease (SCD) is a neglected, chronic, multi-
system disorder that is of growing importance in the
global health context [1, 2]. SCD is caused by the inher-
itance of a mutation in the HBB gene that results in the
production of a structurally abnormal form of β-globin.
This variant form of haemoglobin, known as sickle
haemoglobin or HbS, polymerizes reversibly under low
oxygen tension to alter the shape and rheological prop-
erties of red blood cells, a phenomenon that is central to
the pathophysiology of SCD [3]. Although SCD is most
commonly caused by the homozygous inheritance of
HbS (HbSS), it can also result from the coinheritance of
HbS with other mutations of the HBB gene, most
notable among them being a second structural haemo-
globin variant, HbC, and β-thalassaemia, a condition
characterized by the reduced production of normal
β-globin chains [3].
SCD in resource-limited settings
The sickle mutation has risen to high allele frequencies
in many parts of Africa, India and the Middle East
because carriers (with HbAS) are strongly protected
against death from Plasmodium falciparum malaria [4, 5].
As a consequence, more than 90 % of global SCD births –
at least 280,000 births each year [6] – occur in resource-
limited regions of the world. Nevertheless, in comparison
to the minority of affected subjects who are born in
resource-rich regions, the outlook for these children is
stark. Since the introduction of newborn screening
throughout much of Europe and North America, the
majority of children born with SCD in these regions are
diagnosed early, placed on life-long care, and can expect
to live to middle-age and beyond [7]. By contrast, however,
poor diagnostic facilities coupled with the low priority
afforded to SCD in the health plans of many countries in
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sub-Saharan Africa (SSA) mean that the majority of
children born with the condition on the continent go un-
diagnosed and die from preventable complications before
their fifth birthday [8]. As a consequence, SCD is respon-
sible for an increasing proportion of overall childhood
mortality in SSA, reaching 6 % or more in a number of
countries within the region [9, 10].
Current methods for the diagnosis of SCD
Key to tackling the early mortality of children with SCD
is prompt diagnosis. This allows for the education of
parents about how best to look after their affected chil-
dren and to recognize important danger signs, and for
the prevention of complications through the targeted
use of vaccinations, antibiotics and anti-malarial drugs.
Such measures, which could be easily afforded by many
countries within the region [11, 12], were successful in
reducing the high early mortality that was previously
seen in other parts of the world, and there is no reason
to suspect that the same should not be true if widely im-
plemented in resource-limited settings [10]. However, to
date, diagnostic facilities for SCD remain poor through-
out many such regions, where all too often they are
limited to private facilities and beyond the reach of the
majority who would benefit.
A number of different methods can be used to diag-
nose SCD, of which the most common are haemoglobin
electrophoresis, high performance liquid chromatog-
raphy (HPLC), isoelectric focusing and molecular
approaches such as PCR [13]. However, all require well-
trained staff working with well-maintained equipment in
reasonable laboratory facilities, a reliable supply of
power, and systems for the delivery and storage of re-
agents, the commercial costs of which alone can typic-
ally run to $5–10 per test. Moreover, laboratory-based
approaches require functional systems for sample trans-
port and the return of results. Although pilot newborn
screening studies in a number of resource-limited coun-
tries have used such approaches successfully [14, 15],
they have rarely been rolled out beyond the confines
of time-limited research-based projects. Moreover,
these cost and logistic constraints mean that even
when health workers suspect the condition in older
children, testing for SCD is seldom undertaken. It is in
this context that the widespread availability of a rapid
and reliable diagnostic test could revolutionize the
outlook for children born with SCD in many resource-
limited settings.
The Sickle SCAN™ test
In research published in BMC Medicine, Kanter and col-
leagues show that a new point of care diagnostic device,
called Sickle SCAN™, can be used to accurately diagnose
the most common forms of SCD (HbSS and HbSC)
from a capillary sample of blood, in less than 5 minutes
[16]. This seemingly easy-to-use test employs a sandwich
format chromatographic immunoassay approach for the
qualitative measurement of HbA, HbS and HbC, to-
gether with α-globin as a positive control. The test has a
similar look and feel to devices that are used for the
rapid diagnosis of other conditions, including HIV and
malaria, with which most practitioners in resource-
limited settings will be familiar. Sickle SCAN™ has a
number of potential advantages over traditional labora-
tory methods. Perhaps most importantly, being so rapid
the method could contribute to the immediate manage-
ment of patients in whom clinicians suspect a diagnosis
of SCD, allowing for the real-time communication of
results and appropriate referral to specialist services.
Moreover, the test requires no electricity and should
avoid the cost and added complexity of sample transport
and the feedback of results.
Further work needed
The greatest gains will be delivered if Sickle SCAN™
makes feasible the widespread testing of children as early
in life as possible – preferably at birth (if delivered at a
health facility) or at first contact with a health profes-
sional. However, the high and variable concentration
during early life of red cell fetal haemoglobin (HbF)
means that it cannot be assumed that Sickle SCAN™ will
be equally accurate during this period without further
studies. Such studies are currently under way, the results
of which are anticipated with considerable interest. Simi-
larly, before its wide endorsement, the accuracy of Sickle
SCAN™ needs confirming in larger studies conducted in
multiple communities under real-world conditions. Fi-
nally, a critical issue regarding the likely utility of Sickle
SCAN™ will be cost. While this will obviously be deter-
mined through negotiation between the manufacturers
and their various target groups, it goes without saying
that the more cheaply that Sickle SCAN™ can be made
available, the greater its potential impact.
Conclusions
While Sickle SCAN™ is a welcome development, no gen-
etic test comes without a downside. SCD and its carrier
status are still associated with considerable stigma in
many affected communities [17] and, as for other
chronic conditions, unwelcome consequences can ensue
if testing is conducted in the absence of proper support.
While pre- and post-test counselling by well-trained
individuals should mitigate such consequences to some
extent, better education regarding SCD in affected com-
munities and improved advocacy at every level are of
equal importance. By facilitating the widespread diagno-
sis of SCD in resource-limited settings, Sickle SCAN™
could make a valuable contribution to this process.
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